Nicolas Bery

16PUBLICATIONS
55CO-AUTHORS
ChemotherapyMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Biomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Nov 04, 2026
A cytidine deaminase biodegrader sensitises multiple cancer types to deoxycytidine analogue-based chemotherapies.

|Sep 21, 2026
Correction: Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis.

|Dec 12, 2025
Degradation of LMO2 in T cell leukaemia results in collateral breakdown of transcription complex partners and causes LMO2-dependent apoptosis.

Naphannop Sereesongsaeng, Carole Bataille, Angela Russell

|Aug 30, 2024
Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells.

Audrey Frances, Audrey Lumeau, Nicolas Bery

|Jun 27, 2024
Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies.

Sarah Figarol, Célia Delahaye, Rémi Gence

|Jan 31, 2024
Cytidine Deaminase Resolves Replicative Stress and Protects Pancreatic Cancer from DNA-Targeting Drugs.

Audrey Lumeau, Nicolas Bery, Audrey Francès

Pageof 3

Frequent Collaborators

7 joint publications

Terry Rabbitts

3 joint publications

Pierre Cordelier

2 joint publications

Gilles Favre

2 joint publications

Fernando J Sialana